A
Abnormal involuntary movement scale 18
Acathisia 18
Acetylcholine, falling levels of 97
Acetyl-l-carnitine 106
Afeem 88
Aggressiveness 194
Agitation and aggression 102
Alanine aminotransferase 189
Alcohol use disorder 82
long-term treatment 85
medications for long-term 86t
treatment framework 84fc
Allergy 16
Alpha-2 adrenoceptor agonists 128
Amantadine 19
American Diabetes Association 21t
American Geriatrics Society 177
Amphetamine-based 120
Anger and aggression 117
Angina 91
Anticholinergic delirium 22
administration of 154
adverse effects of 154
classification of 27
for treatment of depression 39b
overdosage of 155
WHO essential medicines 2017 153t
wide range of 26
Antifibrillogenesis drugs 107
Antimalarial drugs 199
administration of 165
long-term treatment 164
overdosage of 169
short-term treatment 163
WHO essential medicines 2017 166t
Anti-Parkinson's medications 193
development of 2
long-term treatment 160
management 16
mechanism of action 9
overdosage of 162
powerful 2
typical 190
administration of 161
adverse effects of 161
availability of 15
blocking actions of 10f
in pregnancy 140
polypharmacy 12
properties of 10
WHO essential medicines 2017 158t
Antiretroviral therapy 199
Antitubercular medications 199
Anxiety and depression 194
advantage and disadvantages of 63
different phases of illness 56t
pregnancy and breastfeeding 64
recommendations treatment of 61t
treatment approaches for 56t
Anxious avoidant personality disorder 115
Apathy 102
Apgar scores 143
Arrhythmogenic 185
Atazanavir 197
Atherogenic dyslipidemia 20
Australian and New Zealand Royal College of Psychiatrists, guidelines 11
Autoimmune disorders 175
Autonomic dysfunction 99
Avoidant personality disorders 110
Azapirone 61
B
Bapineuzumab 106
Barnes Akathisia Rating Scale 18
Behavioral activation 123
Behavioral management 127
Benzamides 128
for alcohol detoxification 83t
for treatment 171
overdose 172
pharmacotherapy with 171
prescribing 172b
short-term pharmacotherapy 171
Bethanechol 22
Biperiden 162
acute, management of 44
long-term prophylaxis for 49
mixed episodes 48
nature of 52
pharmacological
management of 43
pharmacotherapy of
lithium 132
valproate 132
treatment options for 43t
Bipolarity, history suggestive of 40
Birth weight 143
Blood dyscrasias 169
Blood pressure 21
Blurry vision 20
Botulinum toxin injections 129
Bradykinesia 162
Brain imaging 2
Brain injury, post-traumatic 194
Breastfeeding women 142
Bulimia 194
Burning sensation 91
Buspirone 61
C
Cancer-related fatigue 195
Cannabis intoxication 170
Cardiac disorders 123
Cardiovascular conditions 179
Catatonia 3
Cerebrospinal fluid 2
Child's cognitive and linguistic ability guides 119
Chlordiazepoxide 84
Chlorpheniramine 178
Clinical Institute Withdrawal Assessment-Alcohol Revised 82
Clinical practice guidelines 40
Clorazepate 82
Coexisting psychiatric disorders, management of 111
Cognitive continuum 94
Cognitive decline and dementia 94
Cognitive deficits 193
Cogwheel rigidity 162
Common mental disorder 25
Convulsions 162
Corticosteroids drugs 199
Creatine kinase 13
Crisis management 111
Cycloid psychoses 3
Cyclophosphamide 196
Cycloserine 11
CYP2D6 inhibitors 196
CYP3A43, induction of 198
D
Damiana leaf 78
Dapoxetine 71
Dapoxetine, off-label use of 71
Darunavir 197
Deaths due to suicide 25
Deficiency of mental health specialists 148
Dehydroepiandrosterone 78
Delayed ejaculation, pharmacotherapy 72
Delivery, preterm 143
Delusion disorder 3
end stage 15
general management principles of 95
management of special issues 105
neurodegenerative 94
other treatment options 106
pharmacological treatment of 95
psychological symptoms of 103t
reversible causes of 96
subtypes of irreversible 96t
target domains in treatment of 95fc
with lewy bodies 96
with psychosis 4
Depixol, fluanxol 6
choosing an antidepressant 39
etiology of 26f
in pregnancy 41
long-term treatment 152
treatment of 25
with psychosis 4
Depressive episodes 45
Dermatological medications 199
Desire disorder 78
Desire, excitement, orgasm and resolution; model of 68f
Detoxification in opioid dependence 88
Deutetrabenazine 19
Dexmethylphenidate 121
Dextroamphetamine 122
Dextropropoxyphene 88
Dialectical behavior therapy 110
Dibenzodiazepine 5
Diphospho-glucuronosyltransferases 197
Disease, chronic 96
Disease-modifying therapies 107
Disinhibition 194
Disruptive behavior disorders 126
Disruptive mood dysregulation disorder 131
Diversion, risk of 123
Dizziness 73
Doda 88
Double-blind placebo-controlled trials 122
Drug-drug interactions 196
Drugs
absorption 176
allergies 16
development pipeline 107
distribution 176
in consultation-liaison psychiatry 175
in lactation and pregnancy 138
in psycho-oncology 195
interactions with 40
antifungals 198
antitubercular therapy 197
cancer medications 196
contraceptives 198
diabetic medications 198
human immunodeficiency virus medications 197
immunosuppressants 197
metabolism 177
reaction with eosinophilia 16
used in premature ejaculation 72
Dyskinesia, acute 16
Dyspareunia, superficial 78
Dyspepsia 73
Dystonia, acute 16
E
Eating disorders 139
Ebstein's anomaly 140
Ecitalopram 104
Efavirenz 197
Efficacious 73
Endocrine and sexual 22
Endocrine disorders 175
Erectile disorder 73
Erectile dysfunction, pharmacotherapy for 73
Erythema 91
Erythromycin 74
Esterified estrogen 70
Estrogen 78
Eszopiclone 197
European Medicines Agency 74
Extrapyramidal Symptom Rating Scale 18
F
Fear of abandonment 117
Female orgasmic disorder 74
Female sexual interest 70
Flupentixol 6
Fosamprenavir 197
G
Gamma-aminobutyric acid receptors 82
Glomerular filtration rate 188
Glycine 11
Guanfacine and clonidine 120
H
Half-life 83
Hemorrhagic pancreatitis 169
Hepatic impairment 183
Hepatocellular injury 189
Heroin 88
Human sexual response cycle 68
Hydroxyzine 61
Hyperactivity and impulsivity 125
Hypersexuality 194
Hypokinesia 16
Hypomanic symptoms 131
Hypothalamic-pituitary-adrenal 25
Hypothyroidism 96
I
Idiosyncratic reaction 189
Illnesses 130
Immune mediated 189
Immunotherapy, passive 106
Impulse control disorders 193
Impulsiveness 194
Insulin resistance 20
Intellectual disability and developmental delay 14
International Classification of Diseases 111
Intestinal cramps and flatulence 87
Irritable dysphoria 46
L
Leukopenia, mild 168
Lewy body dementias 99
Lipids profile 102
Lisdexamfetamine 122
Liver disease, end-stage 188
Liver injury serum, cholestatic type of 189
Loxapine 17
Lozenge 91
M
Magnesium pemoline 124
Major depressive disorder, developing 25
Malignancy 96
Mascaraed 47
Medication induced 96
Memantine 98
Mental and sexual health 144
Mental health during pregnancy 139
Mental Health Gap Action Programme 148
Mental illness on pregnancy 139
Mentalization-based treatment 110
Metabolic derangements 96
Metabolic risks 20
Metabolite, active 83
Methadone 89
Microsomal cytochrome p450 177
Mirtazapine 27
Modafinil 124
Molindone 17
Monoamine deficiency hypothesis 25
Monoamine oxidase 32
Montgomery-Asberg Depression Rating Scale 45
Mood disorders 130
Mood dysregulation 125
Multiple comorbidities, management of 105
Multiple psychotropic medications, combination of 179
Multiple sclerosis 175
Muscular weakness 169
Myocarditis 185
N
Nasal congestion 73
National Institute of Mental Health 130
National List of Essential Medicines 153
National Mental Health Survey of India 148
Nefazodone 27
Neonatal behavioral syndrome 144
Neurocognitive disorders 94
Neurodegenerative dementia, common forms of 94
Neurodevelopmental disorders 175
Neuroleptic denotes 16
Neuroleptic sensitivity 99
Neurons, presynaptic 26
Neurotransmitters and hormones mediate 68
N-methyl-d-aspartate antagonist 98
Non-Alzheimer's dementia 99
Nonbenzodiazepine antianxiety medications 172
Nonorganic female orgasmic disorders 78
Noxious action 16
O
Omega-3 fatty acids 106
Opioid antagonists 90
Oral inhaler 92
Orgasmic dysfunction 78
Oxazepam 188
P
P450 CYP3A4 enzyme 89
Pain 105
Parkinson symptoms of akinesia 16
Parkinsonian symptoms 128
Pediatric bipolar disorder, pharmacotherapy for 133b
Pediatric obsessive compulsive disorder 135
Pentazocine 88
Persistent pulmonary hypertension 143
Persistent visual hallucinations 99
caution for prescribing medications 115
clinical tip for pharmacological 115t
drug treatment of
anxious-avoidant 114
borderline 112
schizoid, schizotypal and paranoid 111
management of borderline 113b
polypharmacy 116
psychological aspects 116
role of psychotropic medications 111b
treatment of 110
Pharmacodynamic changes in elderly 177
Pharmacokinetic changes 176b
Phenelzine 27
Phenobarbital 198
Phobia 170
Physical symptoms 2
Pill-rolling movements 16
Pimozide 127
Polycystic ovary disease 144
Polymer-based adhesive patch 121
Potentially inappropriate medication 177
Power dynamics 117
Preconception counseling 144
Predominant cognitive 15
and lactation 91
antidepressant impact on 143
antipsychotics in 140
clozapine use in 140
lithium use in early 141
poses 138
Premature (early) ejaculation 71
Prophylactic agent 50
Prophylaxis 49
Protease inhibitors 197
Protein binding 188
Pruritus 91
Psychiatrist, role of 145b
Psychoeducation 55
assessment of 15
disorders with 3t
due to general medical conditions 4
pharmacotherapy of 1
presence of 2
risk syndrome 4
special populations 13
treatment guidelines 10
Psychosocial interventions 62
Psychotic symptoms 160
R
Rebound exacerbation 123
Reserpine 2
Respiratory depression 169
Restricted, repetitive stereotyped behaviors 125
Reward pathway 82f
Ritonavir 197
S
Schizoaffective disorder 3
atypical antipsychotics 129
patient outcomes research team 10
spectrum disorders 130
treatment of 12
typical antipsychotics 129
Schizophreniform disorder 3t
Sedative antihistamines 104
Selective Aβ-42 lowering agents 107
Selective norepinephrine reuptake inhibitors 35f
Selegiline 27
Self-injurious behavior 125
Semagacestat 106
Semisynthetic opioid derived 88
Sensory impairment 105
Septal defects 32
Serine 11
Serotonin reuptake inhibitors 143
Serotonin transporter 26
Sexual disorders, treatment of 69
Sexual response cycle 67
Sexual, side effects 22
Simpson-Angus Scale 18
Sinus tachycardia 185
Sleep disturbance 125
Snuff 91
Sodium valproate 166
Solanezumab 106
Soluble gamma-secretase modulators 107
Specific serotonergic antidepressants 36f
Spheroidal oral drug absorption system 121
Stevens–Johnson syndrome 168
Stimulants 120
amphetamines 122
methylphenidate 120
osmotic-controlled release oral delivery system 120
Subdural hematoma 96
Substance-induced psychoses 4
Sudden cardiac death 186b
Suicide and nonsuicidal self-injury 115
Sulpiride 128
Symbolism of care 117
T
Tadalafil 73
Temazepam 188
Testosterone 78
Tetrabenazine 128
Tetrahydrocannabinol 128
Texas Medication Algorithm Project 10
Thorazine, largactil 6
Thyroid disorders 96
Tiapride 128
Tic disorder 127
atypical antipsychotics 127
pharmacological options for 127
typical antipsychotics 127
Tobacco use disorders 91
Toxic epidermal necrolysis 168
Transient perceptual alterations 1
Treatment for Adolescents with Depression Study 130
Treatment of Early Age Mania Study 132
Treatment of SSRI-resistant Depression in Adolescents 131
Tremors 161
Tricyclic compounds 26
Trifluoperazine 2
Trihexyphenidyl 162
V
Vaginismus 78
Vagus nerve stimulation 50
Valbenazine 19
Varenicline 92
Verbal and physical violence 194
Vesicular monoaminetransporter type 2 inhibitor 128
Vilazodone 27
Vinblastine 196
Vinca alkaloids 196
Vincristine 196
Vision, blurring of 162